We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Here's Why Immune Design Should Be in Your Portfolio Now
Read MoreHide Full Article
On Nov 18, 2016, we issued an updated report on Immune Design Corp. .
Immune Design posted a narrower-than-expected loss in the third quarter while its revenues beat estimates. The top line also improved year over year on the back of milestone payments received under Immune Design’s collaboration with Sanofi (SNY - Free Report) for the development and commercialization of products for the treatment of peanut allergy. The company reported third-quarter results on Nov 9, 2016.
Immune Design’s progress on its pipeline has been quite impressive. The company is currently developing several candidates in the field of immuno-oncology using its ZVex and GLAAS platforms. The key products under development include CMB305 and G100. CMB305 is being evaluated for the treatment of soft tissue sarcoma while G100 is being developed for the treatment of Merkel-cell carcinoma (MCC) and follicular non-Hodgkin’s lymphoma (NHL). The comany has a collaboration with Merck for evaluating G100 in combination with the latter’s anti-PD-1 agent, Keytruda, for the treatment of NHL. Although Immune Design primarily focuses on the development of cancer immunotherapies, it is also making efforts to develop treatments for non-oncology diseases.
Moreover, the company has entered into strategic agreements with other big players like Roche Holding AG (RHHBY - Free Report) and AstraZeneca PLC (AZN - Free Report) , which not only validate its GLAAS platform, but also provide the company with funds in the form of collaboration and license revenues.
However, Immune Design is highly dependent on its collaboration partners for its revenues. Since, its revenues mainly comprise fees from collaboration and licensing agreements, excessive dependence on other companies for revenue growth increases its vulnerability. Moreover, the company has been seeing an increase in expenses due to the ongoing R&D programs.
Also, most Immune Design’s pipeline candidates are in the early stages of development and consequently several years away from commercialization.
In addition to the recommendations that are available to the public on our website, how would you like to follow all Zacks' private buys and sells in real time?
Our experts cover all kinds of trades… from value to momentum . . . from stocks under $10 to ETF and option moves . . . from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises. You can even look inside exclusive portfolios that are normally closed to new investors. Starting today, for the next month, you can have unrestricted access. Click here for Zacks' private trades >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Here's Why Immune Design Should Be in Your Portfolio Now
On Nov 18, 2016, we issued an updated report on Immune Design Corp. .
Immune Design posted a narrower-than-expected loss in the third quarter while its revenues beat estimates. The top line also improved year over year on the back of milestone payments received under Immune Design’s collaboration with Sanofi (SNY - Free Report) for the development and commercialization of products for the treatment of peanut allergy. The company reported third-quarter results on Nov 9, 2016.
Immune Design’s progress on its pipeline has been quite impressive. The company is currently developing several candidates in the field of immuno-oncology using its ZVex and GLAAS platforms. The key products under development include CMB305 and G100. CMB305 is being evaluated for the treatment of soft tissue sarcoma while G100 is being developed for the treatment of Merkel-cell carcinoma (MCC) and follicular non-Hodgkin’s lymphoma (NHL). The comany has a collaboration with Merck for evaluating G100 in combination with the latter’s anti-PD-1 agent, Keytruda, for the treatment of NHL. Although Immune Design primarily focuses on the development of cancer immunotherapies, it is also making efforts to develop treatments for non-oncology diseases.
Moreover, the company has entered into strategic agreements with other big players like Roche Holding AG (RHHBY - Free Report) and AstraZeneca PLC (AZN - Free Report) , which not only validate its GLAAS platform, but also provide the company with funds in the form of collaboration and license revenues.
However, Immune Design is highly dependent on its collaboration partners for its revenues. Since, its revenues mainly comprise fees from collaboration and licensing agreements, excessive dependence on other companies for revenue growth increases its vulnerability. Moreover, the company has been seeing an increase in expenses due to the ongoing R&D programs.
Also, most Immune Design’s pipeline candidates are in the early stages of development and consequently several years away from commercialization.
IMMUNE DESIGN Price
IMMUNE DESIGN Price | IMMUNE DESIGN Quote
Zacks Rank
Immune Design currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Zacks’ Best Private Investment Ideas
In addition to the recommendations that are available to the public on our website, how would you like to follow all Zacks' private buys and sells in real time?
Our experts cover all kinds of trades… from value to momentum . . . from stocks under $10 to ETF and option moves . . . from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises. You can even look inside exclusive portfolios that are normally closed to new investors. Starting today, for the next month, you can have unrestricted access. Click here for Zacks' private trades >>